CJC-1295
CJC-1295 (with DAC)
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Growth Hormone Releasing Hormone (GHRH) Analogue |
| Half-Life | ~6–8 days (with DAC) |
| Administration | Subcutaneous injection |
| Typical Dosage | 1–2 mg weekly (with DAC) or 100 mcg per dose (without DAC) |
| Cycle Length | 8–16 weeks |
| Evidence Level | Moderate Preclinical / Emerging Human |
| Legal Status | Research compound — not FDA-approved for human use |
| Approximate Cost | $35–$70 per vial |
How CJC-1295 Works
Binds to GHRH receptors on pituitary somatotrophs, stimulating sustained GH release over days rather than hours.
CJC-1295 is a modified analogue of growth hormone releasing hormone (GHRH) that has been engineered for extended half-life. The DAC (Drug Affinity Complex) version binds to albumin in the bloodstream, extending its half-life from minutes (native GHRH) to 6–8 days. This creates a sustained elevation of baseline GH levels rather than the sharp, brief pulses produced by GHRPs like Ipamorelin. When combined with Ipamorelin, the two peptides produce synergistic GH release: CJC-1295 raises the baseline and Ipamorelin triggers amplified pulses on top of that elevated baseline.
Evidence Base
Preclinical Evidence
Studies demonstrate dose-dependent increases in GH and IGF-1 levels sustained over multiple days. Animal models show improvements in lean body mass, bone density, and fat oxidation.
Human Evidence
Phase I/II trials in healthy adults and GH-deficient patients demonstrate safe, sustained GH elevation. Studies show 2–10 fold increases in mean GH levels with weekly dosing.
Anecdotal Evidence
CJC-1295 is rarely used as a standalone peptide. Its primary role in the community is as the 'base' of the Ipamorelin/CJC-1295 stack. Users report that the combination produces more consistent body composition improvements and sleep benefits than either peptide alone.
Key PubMed References:
Safety Profile
Side Effects
Water retention, mild fatigue, and injection-site reactions. The sustained GH elevation from the DAC version can cause more pronounced water retention than shorter-acting GH secretagogues.
Contraindications
Same as Ipamorelin: caution in active cancer, diabetes, and pregnancy. The sustained GH elevation warrants careful monitoring in individuals with insulin resistance.
PeptidePilot Assessment
CJC-1295 is almost exclusively recommended by PeptidePilot as part of the Ipamorelin/CJC-1295 combination. It is the preferred choice for users who want sustained GH elevation over the course of a week rather than sharp daily pulses. In our algorithm, it scores highest for users with anti-aging and body composition goals who prefer a lower-frequency injection schedule.
📊 Included in the 22% of users who receive the Ipamorelin/CJC-1295 combination as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.
The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.